ATE444294T1 - Verbindungen und zusammensetzungen als proteinkinaseinhibitoren - Google Patents

Verbindungen und zusammensetzungen als proteinkinaseinhibitoren

Info

Publication number: ATE444294T1
Authority: AT; Austria
Prior art keywords: compounds; compositions; abl; protein kinase; kinase inhibitors
Prior art date: 2005-10-28

Application number

AT06826446T

Other languages

English (en)

Inventor

Advait Nagle

Nathanael S Gray

Original Assignee

Irm Llc

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-28

Filing date

2006-10-20

Publication date

2009-10-15

2006-10-20 Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE444294T1 publication Critical patent/ATE444294T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 4
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
230000002159 abnormal effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 abstract 1
101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
101150036586 FES gene Proteins 0.000 abstract 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
101001074439 Homo sapiens Polycystin-2 Proteins 0.000 abstract 1
101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 abstract 1
101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 abstract 1
101001026882 Homo sapiens Serine/threonine-protein kinase D2 Proteins 0.000 abstract 1
101150003567 Mapk12 gene Proteins 0.000 abstract 1
101150060694 Mapk13 gene Proteins 0.000 abstract 1
102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 abstract 1
108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 abstract 1
102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 abstract 1
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 abstract 1
101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
101100091501 Mus musculus Ros1 gene Proteins 0.000 abstract 1
101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
101150056950 Ntrk2 gene Proteins 0.000 abstract 1
101100202399 Oryza sativa subsp. japonica SAPK4 gene Proteins 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract 1
108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract 1
102100036142 Polycystin-2 Human genes 0.000 abstract 1
101150071831 RPS6KA1 gene Proteins 0.000 abstract 1
101100091511 Rhizobium radiobacter ros gene Proteins 0.000 abstract 1
102100039314 Rho-associated protein kinase 2 Human genes 0.000 abstract 1
101710088493 Rho-associated protein kinase 2 Proteins 0.000 abstract 1
101150105578 SAPK3 gene Proteins 0.000 abstract 1
102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 abstract 1
102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 abstract 1
101150110875 Syk gene Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)

AT06826446T 2005-10-28 2006-10-20 Verbindungen und zusammensetzungen als proteinkinaseinhibitoren ATE444294T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73117905P	2005-10-28	2005-10-28
PCT/US2006/041229 WO2007053343A2 (en)	2005-10-28	2006-10-20	Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE444294T1 true ATE444294T1 (de)	2009-10-15

Family

ID=37964989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06826446T ATE444294T1 (de)	2005-10-28	2006-10-20	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren

Country Status (15)

Country	Link
US (1)	US8592433B2 (de)
EP (1)	EP1940844B1 (de)
JP (1)	JP5102771B2 (de)
KR (1)	KR20080075837A (de)
CN (1)	CN101296928B (de)
AT (1)	ATE444294T1 (de)
AU (1)	AU2006309171A1 (de)
BR (1)	BRPI0617863A2 (de)
CA (1)	CA2626350A1 (de)
DE (1)	DE602006009539D1 (de)
ES (1)	ES2332423T3 (de)
PL (1)	PL1940844T3 (de)
PT (1)	PT1940844E (de)
RU (1)	RU2008120850A (de)
WO (1)	WO2007053343A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101372475B (zh) *	2008-03-19	2012-01-04	南京工业大学	芳杂环取代的二苯脲类衍生物及其用途
CN102014627B (zh) *	2008-04-30	2014-10-29	国家卫生研究院	作为极光激酶抑制剂的稠合双环嘧啶化合物
MX353308B (es)	2008-05-21	2018-01-08	Ariad Pharma Inc	Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
EP2307456B1 (de)	2008-06-27	2014-10-15	Amgen Inc.	Die inhibierung von ang-2 zur behandlung multipler sklerose
US9006252B2 (en)	2008-09-26	2015-04-14	National Health Research Institutes	Fused multicyclic compounds as protein kinase inhibitors
MA33208B1 (fr)	2009-03-25	2012-04-02	Genentech Inc	Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
CN105037364B (zh) *	2009-04-03	2018-04-27	维拉斯通股份有限公司	作为激酶抑制剂的嘧啶取代的嘌呤化合物
WO2010114484A1 (en) *	2009-04-03	2010-10-07	S*Bio Pte Ltd	Pyrimidine substituted purine compounds as kinase (s) inhibitors
IN2012DN01983A (de) *	2009-08-24	2015-07-24	Ascepion Pharmaceuticals Inc
EP2704572B1 (de)	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
CN105153162B (zh) *	2012-04-25	2017-05-03	南京圣和药业股份有限公司	作为蛋白激酶抑制剂的苯基脲类化合物及其应用
WO2013169401A1 (en)	2012-05-05	2013-11-14	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
CN103570723B (zh) *	2012-07-27	2016-07-13	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
BR112015016282A2 (en) *	2013-01-07	2017-07-11	Arog Pharmaceuticals, Inc.	crenolanib for treatment of mutated flt3 proliferative disorders
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
US20170137426A1 (en) *	2014-03-28	2017-05-18	Changzhou Jiekai Pharmatech Co., Ltd.	Heterocyclic compounds as axl inhibitors
CN106467541B (zh)	2015-08-18	2019-04-05	暨南大学	取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
WO2017114275A1 (zh) *	2015-12-31	2017-07-06	成都先导药物开发有限公司	一种抑制rock的化合物及其制备方法与应用
CN108250200A (zh) *	2016-12-28	2018-07-06	中国科学院上海药物研究所	一种具有Axl抑制活性的化合物及其制备和应用
CN107383016A (zh) *	2017-04-14	2017-11-24	江西科技师范大学	含杂芳基酰胺结构的吡咯并嘧啶化合物的制备及应用
WO2019034538A1 (en) *	2017-08-18	2019-02-21	Universität Regensburg	SYNTHESIS, PHARMACOLOGY AND USE OF NEW FMS FLT3 TYROSINE KINASE 3 (FLT3) SELECTIVE INHIBITORS
CN116789670A (zh) *	2022-03-17	2023-09-22	中国科学院合肥物质科学研究院	一种选择性csf1r抑制剂及其用途
TW202413367A (zh) *	2022-08-19	2024-04-01	財團法人國家衛生研究院	Ｔａｍ受體抑制劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4252951A (en) *	1979-10-09	1981-02-24	Eli Lilly And Company	Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU9598601A (en) *	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
EP1578722A4 (de)	2001-10-12	2006-09-06	Irm Llc	Kinaseinhibitorgerüste und verfahren zu deren herstellung
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
EP1684762A4 (de) *	2003-11-13	2009-06-17	Ambit Biosciences Corp	Harnstoff-derivate als kinase-modulatoren
CN1918158B (zh) *	2004-02-14	2011-03-02	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
US7977345B2 (en) *	2004-07-02	2011-07-12	Exelixis, Inc.	c-MET modulators and method of use
US8183248B2 (en)	2005-05-13	2012-05-22	Irm Llc	Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
TW200740820A (en) *	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
DE102005037499A1 (de) *	2005-08-09	2007-02-15	Merck Patent Gmbh	Pyrazolderivate

2006
- 2006-10-20 PT PT06826446T patent/PT1940844E/pt unknown
- 2006-10-20 CA CA002626350A patent/CA2626350A1/en not_active Abandoned
- 2006-10-20 JP JP2008537826A patent/JP5102771B2/ja not_active Expired - Fee Related
- 2006-10-20 CN CN200680040381XA patent/CN101296928B/zh not_active Expired - Fee Related
- 2006-10-20 US US12/088,649 patent/US8592433B2/en not_active Expired - Fee Related
- 2006-10-20 EP EP06826446A patent/EP1940844B1/de not_active Not-in-force
- 2006-10-20 RU RU2008120850/04A patent/RU2008120850A/ru not_active Application Discontinuation
- 2006-10-20 DE DE602006009539T patent/DE602006009539D1/de active Active
- 2006-10-20 WO PCT/US2006/041229 patent/WO2007053343A2/en not_active Ceased
- 2006-10-20 PL PL06826446T patent/PL1940844T3/pl unknown
- 2006-10-20 ES ES06826446T patent/ES2332423T3/es active Active
- 2006-10-20 AT AT06826446T patent/ATE444294T1/de active
- 2006-10-20 BR BRPI0617863-4A patent/BRPI0617863A2/pt not_active IP Right Cessation
- 2006-10-20 AU AU2006309171A patent/AU2006309171A1/en not_active Abandoned
- 2006-10-20 KR KR1020087009969A patent/KR20080075837A/ko not_active Ceased

Also Published As

Publication number	Publication date
WO2007053343A2 (en)	2007-05-10
DE602006009539D1 (de)	2009-11-12
CA2626350A1 (en)	2007-05-10
PL1940844T3 (pl)	2010-03-31
KR20080075837A (ko)	2008-08-19
US8592433B2 (en)	2013-11-26
CN101296928B (zh)	2011-01-19
AU2006309171A1 (en)	2007-05-10
ES2332423T3 (es)	2010-02-04
BRPI0617863A2 (pt)	2011-08-09
US20100324062A1 (en)	2010-12-23
EP1940844B1 (de)	2009-09-30
PT1940844E (pt)	2010-01-06
CN101296928A (zh)	2008-10-29
JP2009513632A (ja)	2009-04-02
WO2007053343A3 (en)	2007-08-09
RU2008120850A (ru)	2009-12-10
JP5102771B2 (ja)	2012-12-19
EP1940844A2 (de)	2008-07-09

Legal Events

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1940844

Country of ref document: EP

Publication	Publication Date	Title
ATE444294T1 (de)	2009-10-15	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
ATE482958T1 (de)	2010-10-15	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
TW200726766A (en)	2007-07-16	Compounds and compositions as protein kinase inhibitors
WO2006124731A3 (en)	2007-03-29	Compounds and compositions as protein kinase inhibitors
TNSN07176A1 (en)	2008-11-21	Compounds and compositions as protein kinase inhibitors
MX2009003649A (es)	2009-04-22	Inhibidores de cinasa de proteina y metodos para utilizarlos.
WO2006101783A3 (en)	2009-04-02	Compounds and compositions as protein kinase inhibitors
WO2007136465A3 (en)	2009-01-22	Compositions and methods for fgf receptor kinases inhibitors
ATE469151T1 (de)	2010-06-15	Pyrrolopyridinderivate als proteinkinaseinhibitoren
TNSN06406A1 (en)	2008-02-22	Compounds and compositions as protein kinase inhibitors
EA200901654A1 (ru)	2010-06-30	Ингибиторы и способы с их использованием
ATE499374T1 (de)	2011-03-15	Verbindungen und zusammensetzungen als proteinkinase-hemmer
EA201000003A1 (ru)	2010-06-30	Ингибиторы протеинкиназ и способы их применения
TNSN06053A1 (en)	2007-10-03	6-substituted anilino purines as rtk inhibitors
PL2081435T3 (pl)	2016-11-30	Inhibitory kinazy tyrozynowej brutona
MX2008001605A (es)	2008-04-14	Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
WO2005039486A3 (en)	2006-03-16	Compounds and compositions as protein kinase inhibitors
MX2009011416A (es)	2009-11-05	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
TH79792A (th)	2006-09-07	สารประกอบและสารผสมที่เป็นสารยับยั้งโปรตีนไคเนส
DE602007013467D1 (de)	2011-05-05	4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
TH98294A (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์